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Abstract
Use of Env in HIV vaccine development has been disappointing. Here we show that, in the presence of a biologically active
Tat subunit vaccine, a trimeric Env protein prevents in monkeys virus spread from the portal of entry to regional lymph
nodes. This appears to be due to specific interactions between Tat and Env spikes that form a novel virus entry complex
favoring R5 or X4 virus entry and productive infection of dendritic cells (DCs) via an integrin-mediated pathway. These Tat
effects do not require Tat-transactivation activity and are blocked by anti-integrin antibodies (Abs). Productive DC infection
promoted by Tat is associated with a highly efficient virus transmission to T cells. In the Tat/Env complex the cysteine-rich
region of Tat engages the Env V3 loop, whereas the Tat RGD sequence remains free and directs the virus to integrins
present on DCs. V2 loop deletion, which unshields the CCR5 binding region of Env, increases Tat/Env complex stability. Of
note, binding of Tat to Env abolishes neutralization of Env entry or infection of DCs by anti-HIV sera lacking anti-Tat Abs,
which are seldom present in natural infection. This is reversed, and neutralization further enhanced, by HIV sera containing
anti-Tat Abs such as those from asymptomatic or Tat-vaccinated patients, or by sera from the Tat/Env vaccinated monkeys.
Thus, both anti-Tat and anti-Env Abs are required for efficient HIV neutralization. These data suggest that the Tat/Env
interaction increases HIV acquisition and spreading, as a mechanism evolved by the virus to escape anti-Env neutralizing
Abs. This may explain the low effectiveness of Env-based vaccines, which are also unlikely to elicit Abs against new Env
epitopes exposed by the Tat/Env interaction. As Tat also binds Envs from different clades, new vaccine strategies should
exploit the Tat/Env interaction for both preventative and therapeutic interventions.
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Introduction
HIV-1 preventative vaccines based on the HIV Env antigen
have either failed or shown marginal protection [1,2,3], indicating
that Env is not sufficient to protect against infection and that
innovative approaches are needed. Approaches employing the
HIV regulatory Tat protein have been shown to contain virus
replication, preventing disease onset and/or progression in
monkey models [4–9] (http://www.avip-eu.org, http://www.
hiv1tat-vaccines.info). The Tat-based vaccine has then been
advanced to preventative and therapeutic phase I trials showing
safety and immunogenicity [10–12] and has recently demonstrated
promising efficacy in a phase II therapeutic trial in HAART-
treated subjects [13].
A large body of evidence provides the rationale for inclusion
of Tat in novel HIV/AIDS preventative vaccine candidates.
The Tat protein is released during acute infection of T cells by
a leaderless secretory pathway [14–16] and is present in tissues
and sera of infected individuals as well as on HIV virus particles
[17–21]. Extracellular Tat is mostly bound to heparan sulfate
proteoglycans (HSPG) of the extracellular matrix (ECM)
[16,17], and engages the arginine-glycine-aspartic acid (RGD)-
binding integrins avb3, a5b1 and avb5 on activated endothelial
cells and co-stains with these integrins in tissues from infected
individuals [17,22–28]. These integrins are highly expressed by
DCs and macrophages, which are known: I) to be a main target
of HIV at the portal of entry, II) to favor the establishment and
spreading of the infection, and III) to become viral reservoirs in
chronic infection. Thus, these cells appear to be key to initiate a
self-propagating infection at the portals of entry, which, in turn,
is essential to establish a self-renewing virus reservoir in regional
lymph nodes required for a persistent infection. By targeting
DCs, extracellular Tat also induces their maturation with
cytokine production and proteasome activation [29–31], leading
to increase and hierarchy modification of CTL epitope
presentation of heterologous antigens including HIV [31,32].
This may result in excessive and improper immune stimulation
that prepares target cells for virus propagation. Finally,
extracellular adherent Tat can efficiently increase virus trans-
mission to T cells [33].
Of note, anti-Tat Abs, which are uncommon in natural
infection and present in about 20% of asymptomatic individuals,
were reported to correlate with non progression to AIDS in
humans and shown to inhibit HIV infection in vitro [34–38].
Further, promising efficacy data were obtained in non-human
primates, where prevention or containment of infection at the
portal of entry or reduction of peak viral load and CD4 decay
were observed in monkeys immunized parenterally with Tat
combined with Env and challenged with SHIV89.6P or
SHIVSF162 [39–41].
Therefore, novel vaccine strategies combining Tat and Env
antigens are being developed with the aim of inducing broad
cellular and humoral immune responses able to kill early the
infected cells, as well as to neutralize infectious virions, acting
together to dampen or to block initial HIV infection and
dissemination (http://www.avip-eu.org) [42].
Here we show that mucosal (nasal) vaccination with Tat and
trimeric V2-deleted (DV2) Env proteins combined prevents virus
spreading from the portal of entry to regional lymph nodes in
monkeys and, consequently, virus dissemination and establishment
of a virus reservoir. This is because Tat forms with Env a new virus
entry complex by binding the V3 loop of Env and by using RGD-
binding integrin-receptors to target and to promote virus entry and
productive infection of DCs and likely other cell types at the
portals of entry expressing RGD-binding integrins. This occurs
with both R5 and X4 HIV variants and with trimeric Env from
different clades. Of note, by binding to Tat, Env appears to be
shielded against HIV neutralizing Abs, which in the presence of
Tat are much less effective. In contrast, in the presence of Tat, Abs
against both Tat and Env restore and further increase neutrali-
zation of HIV entry into DCs and cell infection. This is observed
with both natural and vaccine-induced anti-Tat Abs from sera of
HIV-infected individuals and with sera from Tat/Env vaccinated
monkeys.
These data indicate that both anti-Tat and anti-Env Abs are
required to block HIV acquisition and spreading and have key
implications for new strategies in both preventative and therapeu-
tic HIV vaccine development.
Materials and Methods
Ethics Statement
Adult male cynomolgus monkeys (Macaca fascicularis) were
housed at the National AIDS Center, Istituto Superiore di Sanita`
(ISS), according to the European guidelines for non-human
primate care (ECC, Directive No. 86–609, Nov. 24, 1986).
Animal experiments were approved by the Quality and Safety
Committee for Animal Trials of the ISS. All clinical procedures
were performed upon anesthesia with 7–10 mg/kg Zoletil (a
combination of Tiletamine and Zolazepam).
Studies in humans were conducted according to the principles
of the Declaration of Helsinki and all subjects signed an informed
consent. The ISS T-002 clinical trial (ClinicalTrials.gov
NCT00751595) [13] was approved by the competent authority
(General Director of the Coordinator Clinical Center, Policlinico
of Modena, Modena) and by the Ethics Committees of each
participating clinical center (Policlinico of Modena, Modena;
Arcispedale S. Anna, Ferrara; Istituti Fiosterapici Ospitalieri San
Gallicano, Rome; Policlinico of Bari, Bari; Ospedale S.M. Goretti
Latina; Fondazione S. Raffaele, Milan; Ospedale S. Maria
Annunziata, Florence; Ospedale Luigi Sacco, Milan; Spedali
Civili, Brescia; Ospedale A. di Savoia, Turin).
Production and Purification of Recombinant Biologically
Active HIV-1 Tat, cys22 Tat and Env Proteins
The HIV-1 Tat and cys22 Tat proteins from human T
lymphotropic virus type IIIB-BH-10 (subtype B) were expressed
in Escherichia coli, purified to homogeneity by heparin affinity
chromatography and reverse HPLC, and handled as described
previously [15,16,29]. In brief, to prevent oxidation that occurs
easily because Tat contains seven cysteines, the Tat protein was
stored lyophilized at -80uC and resuspended in degassed buffer
before use. To prevent attachment of the protein to surfaces,
plastic tips and vials were previously rinsed in 0.1% PBS-BSA (Tat
buffer) or in RPMI 1640 supplemented with 20 mM HEPES
(Sigma-Aldrich, St. Louis, MO), 100 U/mL penicillin, 100 mg/
mL streptomycin, 2 mM L-glutamine (Life Technologies, Paisley,
U.K.), and 15% FBS (HyClone Laboratories, Logan, UT)
(complete medium). In addition, because Tat is also photo- and
thermo-sensitive [15,16,29], the handling of the protein was
always performed in the dark and on ice. Different protein lots
were used with reproducible results. In all lots endotoxin
concentration was below the detection limit (,0.02 EU/mg), as
determined by the Lymulus Amoebocyte Lysate analysis (Pyr-
ochrome, Associates of Cape Cod, Falmouth, MA). The purified
Tat protein was fully biologically active, as determined by the
rescue assay on HLM-1 cell line carrying a Tat-defective HIV
provirus [15,16], by the induction of transcription in TZM-bl cells,
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which contain a luciferase reporter gene under the transcriptional
control of the HIV LTR and are commonly used to assess HIV
infectivity (Fig. S1), as well as by Tat uptake by monocyte-derived
dendritic cells (MDDCs) evaluated by intracellular staining for Tat
in flow cytometry [29]. This assay constitutes the potency test for
HIV-1 Tat protein, since it is highly specific for the reduced form
of Tat (uptake does not occur with the oxidized form), and is
strictly dose-dependent, allowing a precise determination of the
content of active protein in the preparation. Cys22 Tat is a clade B
Tat protein carrying a cysteine to glycine substitution at position
22 (cys22 Tat), which renders the protein transactivation-silent (Fig.
S1) [43] although is taken up by MDDCs as well as wild type (wt)
Tat [29].
Monomeric and trimeric wt or DV2 Env molecules from clade
B SF162 HIV have been described elsewhere [44]. For the DV3
Env molecule, the partial V3 loop deletion was generated by
deleting residues 301 to 315 and 317 to 319, and by introducing
an Ala to Gly and an Ile to Ala substitution at position 316 and
320, respectively, in SF162 gp140 [45].
Monkey Studies
Adult healthy male cynomolgus monkeys (Macaca fascicularis)
were imported from the Mauritius breeding colony and were
matched for age and weight. All monkeys were negative for
infections with simian immunodeficiency virus (SIV), type D
simian 1, 2, 3, 5 retroviruses (SRV) and simian T cell leukaemia
(STLV-I) viruses, simian herpes B virus, cytomegalovirus, Ebola
and Marburg viruses. They were housed at the National AIDS
Center, ISS, in an authorized P3 facility in single stainless steel
cages according to the National (Ministry of Health D.L. 27/1/
1992 n. 116) and European guidelines for non-human primate
care (ECC, Directive No. 86–609, Nov. 24, 1986; Refinement,
Reduction and Replacement towards the use of animals for
scientific procedures. 99/167/EC: Council Decision of 25/1/99).
Figure 1. Virological outcome in Tat/Env-vaccinated or control monkeys after intrarectal challenge with the SHIVSF162P4cy (70
MID50). Box plots of (A) Viral RNA, (B) proviral DNA in blood at 2, 3, 4 and 5 weeks after challenge, respectively; and (C) proviral DNA at week 4 after
challenge in rectal tissue (RT) and inguinal lymph nodes (LN). Statistical analysis was performed by the one-sided Wilcoxon rank sum test. Red:
monkeys vaccinated with Tat/Env (n = 6); blue: control animals (n = 6).
doi:10.1371/journal.pone.0048781.g001
Tat Binds Env and Competes Anti-HIV-1 Antibodies
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e48781
The temperature was maintained at 21–23uC and humidity
ranged from 50 to 60% with 10–15% air changes per h. The light
cycle was 12-h light/12-h dark. Animals were fed a commercial
maintenance chow (Rieper, Mucedola s.r.l., Settimo Milanese,
Italy) supplemented biweekly with fresh fruit. Water was supplied
ad libitum. Animal experiments were approved by the Quality and
Safety Committee for Animal Trials of the ISS. All clinical
procedures were performed upon anesthesia with 7–10 mg/kg
Zoletil (a combination of Tiletamine and Zolazepam). Animals
were examined clinically and weight and rectal temperature were
measured while under ketamine hydrochloride anaesthesia (10 mg
Kg-1, intramuscularly). Blood samples for haematological analysis
and for immunological and virological assays were taken in the
morning prior to feeding. All monkeys were observed daily for
behavior, local reactions after immunizations, and clinical signs of
disease. Serum biochemical/hematological parameters and animal
weight were assessed on a regular basis, according to the blood
drawing schedule. No local reactions were recorded after
immunizations and all safety-related parameters evaluated were
in the normal range at all times. All animals lived throughout the
study.
For immunization, biologically active HIV-1 Tat protein
(10 mg) was mixed with trimeric DV2 Env protein (100 mg). The
mixture was then given intranasally (150 mL per nostril) in the
presence of the adjuvant LTK-63 (30 mg) [46] to 6 cynomolgus
macaques (weeks 0, 4, 8), followed by subcutaneous injections
(weeks 24 and 36) of Tat (10 mg) combined with trimeric DV2 Env
(100 mg) proteins in the presence of the Alum adjuvant. Six
additional monkeys received adjuvants only (controls). At week 44
all macaques were challenged intrarectally with 70 MID50 of the
R5-tropic cynos-adapted SHIVSF162P4cy (Table S1), which had
been titrated intrarectally in 10 cynomolgus monkeys [41].
Inguinal lymph nodes and rectal mucosa samples were removed
surgically under ketamine hydrochloride general anesthesia from
all vaccinated and control monkeys at week 4 after the challenge.
The tissues were therefore minced to obtain single cell suspension
for detection of proviral DNA.
SHIV RNA in plasma was quantitated by nucleic acid
sequenced-based amplification using TaqMan Real-Time RT-
PCR assay with a threshold limit for detection of 50 RNA Eq/mL
as previously described [47]. DNA was extracted from whole
blood using the QIAmp Blood Kit (QIAGEN, GmbH, Hilden,
Germany) and from lymph nodes or rectal mucosa using the
QIAmp DNA Mini Kit (QIAGEN, GmbH, Hilden, Germany).
SHIV proviral copy number was determined using TaqMan Real-
time PCR utilizing 1 mg of DNA and amplifying a region of 71 bp
within the gag region of SHIV [48]. The lower limit of detection
was 1 SHIV proviral copy/mg of DNA.
Production of Recombinant Replication Defective Viruses
and Virus Titration
Single-cycle, luciferase-expressing HIV-1 SF162LUC virus was
generated by cotransfection of 293T cells with pNL4-3.Luc.R- E-
and pCAGGS SF162 gp160 (obtained from Dr. Nathaniel Landau
and Drs. L. Stamatatos & C. Cheng-Mayer, respectively, through
the NIH AIDS Research and Reference Reagent Program).
The single-cycle replication, Tat-independent pseudovirus
carrying GFP as gene reporter (VP/SF162) was generated by
transient transfection of 293 cells by the calcium phosphate
method using pMDLg/RRE, pRSV-Rev (Invitrogen, Life Tech-
nologies, Paisley, U.K.), pEF-GFP [49] and the plasmid encoding
the envelope protein from HIV (pCAGGS-SF162gp160 obtained
from Drs. L. Stamatatos & C. Cheng-Mayer through the NIH
AIDS Research and Reference Reagent Program) [50]. This virus
does not rely on Tat expression since it does not contain any TAR
sequence or Tat coding sequence.
The single-cycle Tat-producing HIV (VSV-G/HIV) was
generated by cotrasfection of 293 cells using an envelope deleted
HIV plasmid [52] and a VSV-G expression vector [50] as already
described [33]. The supernatants harvested from the transfected
293T or 293 cells were collected after 48 h and filtered through
0.45 mm pore-size filters (Millipore, Billerica, MA, USA). Pseudo-
virus supernatants were assayed for reverse transcriptase (RT)
activity [51] to determine virus titers (cpm/mL).
MDDC Cultures and Infection Experiments
Monocyte-derived dendritic cells (MDDCs) were obtained by
culturing monocytes from healthy donors for 6 days in medium
containing GM-CSF (500 U/mL; R&D Systems, Minneapolis,
USA) and IL-4 (1,000 U/mL; R&D Systems), as previously
described [29]. DC maturation was induced by LPS (1 mg/mL)
(Sigma-Aldrich, Milano, Italy). MDDC phenotype was assessed by
Figure 2. Enhancement by soluble Tat of HIV-1 infection in MDDCs. Peak infection fold increase reached 3–8 days after infection with the R5
pSF162LUC in MDDCs from 10 different donors. The virus was pre-incubated with 1 mM cys22 Tat or with PBS-0.1% BSA (control buffer). Fold increase
were calculated as the ratio between the RLU from MDDCs infected with virus pre-incubated with cys22 Tat and RLU from MDDCs infected with virus
pre-incubated with control buffer (baseline RLU: 298.95) (both values had been previously subtracted of the uninfected MDDCs RLU background).
doi:10.1371/journal.pone.0048781.g002
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detection of specific surface markers (CD1a, CD14, CD40, HLA-
DR, CD83 and CD86) as described [29]. Purity of MDDCs was
always $99% as assessed by flow cytometry.
For infection experiments with soluble Tat, pseudotyped
SF162LUC virus (4.46105 or 1.26106 cpm of RT activity/
16106 cells) was incubated with cys22 Tat protein at the indicated
concentrations or control buffer (PBS - 0.1% BSA) in a 2 or 1 mL
volume for 30 min at 37uC prior to infection of immature MDDC
cultures. After 2 h at 37uC, cells were extensively washed and
cultured for 7 days. Between 3 and 8 days post infection, 36105 or
66105 cells, respectively, were lysed and analyzed for luciferase
activity by using a Victor luminometer (Perkin-Elmer Life Science,
Shelton, CT). Results were expressed in Relative Light Unit
(RLU). Experiments were carried out in duplicate.
For infection experiments on adherent Tat, plates were coated
with 0.01 or 0.1 mM Tat, 0.5 mL/well, in a 24-wells plate
overnight (O/N) at 37uC, washed with 0.5 mL of PBS with Ca/
Mg +0.1% BSA and blocked with the same buffer at 37uC for 2 h.
MDDCs (16106) were then seeded on the plates and infected for
2 h at 37uC with HIV SF162 (titer: 16106 TCID50/mL, used at
Figure 3. Tat-mediated entry of VLPs expressing R5 or X4 Env into MDDCs. (A) and (B): entry in immature MDDCs of null-VLPs (control) or
(A) VLPs expressing R5-Env (HIV-1 BaL) (VLP-R5Env) or (B) VLPs expressing X4-Env (HIV-1 HXBc2) (VLP-X4Env), in the absence or presence of increasing
concentrations of cys22 Tat after 4 h of incubation, evaluated by flow cytometry. Results are shown as either dot-plot (A) or histograms (B). SSC: side
scatter. Numbers in the insets represent the percentage of GFP positive cells. (C) Confocal microscopy analysis of VLP-R5Env entry into MDDCs in the
presence of cys22 Tat (60 nM) after 4 h of incubation (0.2 mm optical sections form the apical to the basal cell side).
doi:10.1371/journal.pone.0048781.g003
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1:10 dilution). Infection was evaluated as p24 antigen content by
quantitative ELISA (Innotest HIV antigen Mab, Innogenetics,
Gent, Belgium), according to the manufacturer’s instructions.
For the co-culture infection experiments, CEMss cells produc-
ing Tat (CEMss-Tat) and TZM-bl cells infected or not with the
Tat-independent single-cycle VP/SF162 were used. CEMss cells
(36105) were suspended in 0.1 mL of VSV-G/HIV supernatants
(76105 cpm), incubated for 2 h, then washed three times with
PBS, resuspended in complete medium and cultured for an
additional 24 h. Tat production by CEMss cells was evaluated by
immunofluorescence assay. After 24 h, CEMss-Tat cells were co-
cultured with TZM-bl cells (36105) in the presence or absence of
VP/SF162 (160,000 cpm). Cells and virus were incubated for 4 h
in a small volume at 37uC and then diluted to 0.5 mL with
complete medium and cultured in a 24-well plate. After 4 days of
co-culture, cells were analyzed for GFP expression by flow
cytometry, using a FACSCalibur analyzer (Becton Dickinson).
Results were expressed as Mean Fluorescence Intensity (MFI).
For experiments of infection transmission to CD4+ T cells,
MDDCs were seeded on 24-well plates coated with either wt Tat
(0.1 mM) or with control buffer, and infected for 2 h at 37uC with
HIV SF162 (titer: 106 TCID50/mL, used at 1:10 dilution). The
culture supernatants were collected at different time points (3, 7
and 10 days) and added to CD4+ T cell blasts previously
stimulated O/N with PHA (26106/well, 24 well/plate) for 2 h at
37uC in the presence of IL-2 (50 IU/mL, Sigma, Italy). CD4+ T
cells were then collected, extensively washed and plated again with
IL-2. The CD4+ T cell culture supernatants were collected at 3, 7
and 10 days, and tested for p24 antigen content by ELISA.
In blocking experiments of MDDC infection with anti-integrin
Abs, MDDCs were pre-incubated with monoclonal Abs (mAbs)
directed against the a5b1, avb3 and avb5 integrins (10 mg/mL
each) (Chemicon International, Temecula, CA), or a control
isotype mAb (30 mg/mL) (mouse IgG1, BD Biosciences Pharmin-
gen, San Diego, CA), for 30 min at 4uC prior to infection and then
experiments continued as described above.
In neutralization experiments of MDCC infection with sera
from HIV-infected individuals vaccinated with Tat, pseudotyped
SF162LUC virus (56104 cpm of RT activity/16106 cells) was
incubated on 24-well plates coated with cys22 Tat (0.01 mM,
0.5 mL/well) or with BSA for 10 min at room temperature prior
to the addition of 1/30 dilution of serum obtained before or after
Tat vaccination. The sera had identical anti-Env IgG titers, as
assessed by ELISA. After 1 h at 37uC, immature MDDCs were
added to the plates (0.56106 cells/well) and cultured for 48 h.
Cells were then lysed and analyzed for luciferase activity and
results expressed in RLU. Infection was conducted in duplicate.
Production of R5 and X4 Env-VLPs and Tat-mediated VLP
Entry by Flow Cytometry and Confocal Microscopy
Fluorescent VLPs were obtained essentially as described [53] by
transient transfection of 293T cells by the Lipofectamine-2000
(Invitrogen) method using the pCMVdelta R8.74 HIV-1 packag-
ing vector and the immediate-early CMV promoted vectors
expressing NefG3C-GFP and the R5 (HIV-1 BaL) or X4 (HIV-1
HXBc2) envelope proteins, quoted as VLP-R5Env or VLP-
X4Env, respectively. As control, VLPs without envelope protein
were used (null-VLPs). From 48 to 72 h later, the supernatants
were harvested, clarified, and concentrated by ultracentrifugation
on 20% sucrose cushion at 100,000 g, for 2 h at 4uC. VPLs were
tested by western blot using anti-HIV-1 Gag (clone AG3.0), anti-
HIV-1 Nef (clone ARP 444) and the HT-3 anti-HIV-1 Env mAb
(AIDS Research and Reference Reagent Program). VLP prepa-
rations were titrated by both measuring HIV-1 CAp24 contents by
quantitative ELISA (Innogenetics) and RT assay.
For VLP entry experiments, after pre-incubation with different
concentrations of Tat or control buffer for 1 h at 4uC, VLPs were
added to immature MDDCs (26104) and spinoculated at 150 g for
30 min at room temperature. Cells were incubated for 4 h at
37uC, then treated for 10 min with trypsin at 37uC to remove
residual cell membrane bound VLPs, centrifuged, fixed and
analyzed by flow cytometry, fluorescence microscope, and
Figure 4. Tat released by producing T cells increases entry and infection of a Tat-independent replication-incompetent SF162
pseudovirus. CEMss cells were either infected (CEMss-Tat) or not infected (CEMss) with VSV-G/HIV. After 24 h cells were co-cultured for 4 days with
TZM-bl cells in the presence (TZM-bl/VP-SF162) or absence (TZM-bl) of a Tat-independent GFP-expressing single-cycle HIV-1 SF162 virus (VP/SF162),
and then GFP expression evaluated by flow cytometry. Results are expressed as MFI fold increase with respect to the TZM-bl + CEMss co-culture
(baseline MFI: 1.9).
doi:10.1371/journal.pone.0048781.g004
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confocal microscope. Results are express as the percentage of
fluorescent cells.
For confocal microscopy analysis, VLP challenged MDCCs
were fixed in buffered formaldehyde (2% v/v). Phase-contrast and
fluorescence images were recorded with an Olympus IX-81
device.
In integrin blocking experiments, prior to the addition of VLP-
R5Env, MDDCs were incubated at 4uC for 2 h in the presence of
either mAbs directed against the a5b1, avb3 and avb5 integrins
combined (10 mg/mL each) or a control isotype mAb. VLPs were
then added and the experiments continued as described above.
Immuno-scanning Electron Microscopy Analysis of HIV
Bound to Tat-coated Latex Beads
Latex beads (16109, mean diameter 2.4 mm) (Interfacial
Dynamics Corporation, Portland, USA) were incubated for 1 h
at room temperature with 10 mg of Tat or control buffer, washed
three times with 30 mM Na2CO3, 70 mM NaHCO3, (pH 9.5),
and incubated for 1 h at 37uC with either concentrated HIV
(HXBc2) supernatants or with fresh medium. Beads were then
washed three times with PBS-0.1% BSA and incubated for 45 min
at 37uC with 1:100 dilution of anti-gp120 rabbit Abs (Intracel
Corporation, Frederick, MD) in the same buffer. After incubation,
beads were washed with control buffer and then incubated with
1:50 dilution of 5 nm gold-conjugated anti-rabbit IgG Abs (Sigma
Chemical Company, St. Louis, MO) in the same buffer. After
45 min at 37uC, the beads were washed with 0.2 M cacodylate
buffer and then fixed with 2.5% glutaraldehyde in cacodylate
buffer for 15 min at room temperature. After washing with
distilled water, gold particle labelling was amplified with silver
enhancement solution (Sigma Chemical Company) according to
the manufacturer’s instructions. For both secondary electrons and
backscattered electron observations, samples were transferred on
glass coverslips, air-dried, and carbon-coated, and examined with
a Cambridge Stereoscan 360 scanning electron microscope.
Tat and Tat/Env Entry into MDDCs and Blocking by Anti-
integrins mAbs
Increasing concentrations of Tat (0, 2, 6, 18, 54, 162, 486 nM)
were added to MDDCs (26105 cells/mL), and after 10 min
incubation, cells were washed with cold medium and treated for
5 min at 37uC with trypsin-EDTA (Life Technologies, Paisley,
Figure 5. Adherent Tat binds HIV particles and increases MDDC productive infection and transmission to T cells. (A) Immuno-
scanning electron microscopic analysis of HIV bound to Tat-coated latex beads. Images obtained with secondary electrons (left panels) or with
backscattered electron (right panels) are shown. Latex beads were incubated with control buffer and HIV (A, B); with Tat and medium (C, D); or with
Tat and HIV (E, F). Bar represents 5 mm. (B) MDDC infection with HIV SF162 on adherent wt Tat at different time points after infection. Infection of
MDDCs from 2 different donors was carried out on plates coated with wt Tat (0.01 mM for donor 1, 0.1 mM for donor 2) or control buffer. Infection fold
increase was calculated as the ratio between the content of p24 antigen detected in the supernatants of MDDCs seeded on adherent Tat and that
detected in the supernatants of MDDCs seeded on control buffer (baseline, for donor 1, p24 was 154 and 119 pg/mL at day 7 and 10, respectively; for
donor 2, p24 was 38 and 159 pg/mL at day 7 and 10, respectively). (C) Infection of PHA-activated CD4 T cell blasts with supernatants from MDDCs
infected with HIV SF162 on plates coated with Tat wt (0.1 mM) or with control buffer (BSA). Infection was evaluated at the indicated time points by
measuring p24 antigen in the culture supernatants in duplicate wells.
doi:10.1371/journal.pone.0048781.g005
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UK) to remove cell-surface bound protein. After fixation and
permeabilization (Perm Solution, BD Biosciences), MDDCs were
stained with an affinity-purified rabbit polyclonal anti-Tat IgG Abs
(Diatheva, Fano, Italy) or rabbit IgG control Abs (ICN Biomed-
icals, Opera, Italy), followed by FITC-conjugated anti-rabbit Ig
(Pierce, Rockford, IL), as described [29]. Fluorescence was
analyzed by flow cytometry, and results were expressed as the
percentage of Tat positive cells as compared to isotype Ab stained
samples. The values from non-permeabilized cells were subtracted.
For Env uptake experiments, a fixed concentration of mono-
meric and trimeric wt or DV2 Env molecules from clade B, A, or
C (3.52 mM in protein subunit) was incubated at 25uC in degassed
PBS alone or in the presence of increasing concentrations (0.2 –
48.6 mM) of Tat for 10 min. The protein samples were then added
Figure 6. Anti-integrin antibodies block the enhancement of MDDC infection induced by soluble or adherent Tat. (A) pSF162LUC
infection of MDDCs for 8 days in the presence of soluble cys22 Tat (0.1 or 1 mM) and a combination of mAbs directed against the a5b1, avb3 and avb5
integrins (10 mg/mL each) or the control isotype mAb (30 mg/mL). For each Tat concentration (Tat 0.1 mM, blu bar; Tat 1 mM, red bar) infection fold
changes were calculated as the ratio between RLU from MDDCs pre-incubated with the control isotype mAb in the presence and in the absence of
Tat (baseline RLU: 97) or as the ratio between RLU from MDDCs pre-incubated with anti-integrin mAbs in the presence and in the absence of Tat
(baseline RLU: 112) (all values had been previously subtracted of the uninfected MDDC RLU background). Experiments were performed in duplicate.
(B) Infection of MDDCs at different time points in the presence of coated wt Tat (0.01 mM for donor 1, 0.1 mM for donor 2) and of mAbs directed
against the a5b1, avb3 and avb5 integrins (10 mg/mL each) or the control isotype mAb (30 mg/mL). Fold reduction of infection was calculated as the
ratio between the content of p24 antigen detected in the supernatants of MDDCs seeded on adherent Tat in the presence of anti-integrin mAbs and
that detected in the supernatants of MDDCs seeded on adherent Tat in the presence of the control isotype mAb (baseline, for donor 1, p24 was 186
and 479 pg/mL at day 7 and 10, respectively; for donor 2, p24 was 135 and 538 pg/mL at day 7 and 10, respectively). Experiments were performed in
duplicate.
doi:10.1371/journal.pone.0048781.g006
Figure 7. Entry of Tat or R5 Env-VLPs in MDDCs and block by anti-integrin antibodies. (A) Entry of wt Tat into MDDCs from 3–10 different
donors (depending on the anti-integrin mAbs used), in the presence of mAbs against the indicated integrins alone or combined, a control isotype
mAb, or nil (buffer). (B) Entry of cys22 Tat into MDDCs from 3 different donors and block by the combined anti-integrin mAbs versus an Ig control
isotype mAb. The percentages of Tat positive cells +/2 standard deviations are shown. (C) Entry of VLP-R5Env (BaL) in MDDCs in the presence of Tat
and block by anti-integrin mAbs or an Ig control isotype mAb. The percentages of fluorescent cells are shown. A representative experiment out of 4
performed is shown.
doi:10.1371/journal.pone.0048781.g007
Tat Binds Env and Competes Anti-HIV-1 Antibodies
PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e48781
to MDDCs (26105 cells/ml) at a 1:100 final dilution. Cells were
washed with cold medium and treated as described above for Tat
uptake experiments, and stained with an anti-gp120 (NeoMPS
Strasbourg, France) or rabbit IgG control Abs, followed by FITC-
conjugated anti-rabbit Ig (Pierce). Results were expressed as
described above.
Figure 8. Tat-mediated entry of Env molecules from different clades in MDDCs and block by anti-integrins antibodies. (A) Clade B
trimeric wt Env (twt Env), trimeric DV2 Env (tDV2 Env), monomeric wt Env (mwt Env), or monomeric DV2 Env (mDV2 Env) and (B) clade A and C
trimeric wt Env (twt Env) molecules were incubated with control buffer or increasing concentrations of Tat, and then added to MDDCs at 1:100 final
dilution. Cells were then stained for intracellular Env. Open circles: control isotype mAb; filled circles: anti-integrin mAbs directed against the a5b1,
avb3 and avb5 integrins (10 mg/mL each). Data from the same donor out of 3–8 donors tested are shown. Results are expressed as the percentage of
Env-positive cells.
doi:10.1371/journal.pone.0048781.g008
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In integrin blocking experiments, prior to the addition of the
proteins, MDDCs were cultured at 4uC for 2 h in the presence of
mAbs directed against the a5b1, avb3 and avb5 integrins alone or
combined (10 mg/mL each), or with a control isotype mAb.
Results were expressed as described above.
Blocking of Trimeric DV2 Env Entry or Tat/DV2 Env entry
in MDDCs by Anti-DC-SIGN and Anti-integrin mAbs
MDDCs (26105 cells/mL) were incubated for 60 min in the
presence of 20 or 50 mg/mL of the anti-CD209 mAbs (DC-SIGN)
(Beckman Coulter), anti-integrins mAbs (Chemicon International),
an IgG1 control isotype or nil, washed twice with PBS and then
incubated for 10 min with 35 or 70 nM trimeric DV2 Env (SF162)
prior to Env intracellular staining and flow cytometry analysis.
In the experiments of trimeric DV2 Env/Tat complex entry in
MDDCs, cells were incubated, as previously described, in the
presence of 50 mg/mL of the anti-CD209 mAb and anti-integrins
mAbs or a control isotype mAb, and then incubated for 10 min
with trimeric DV2 Env (70 nM) previously complexed with Tat at
different concentrations (50, 16.67 and 5.56 nM) prior to Env
intracellular staining and flow cytometry analysis. In both settings,
results were expressed as the percentage of Env-positive cells.
Blocking of Tat/Env Complex Binding to PBL by an Anti-
CD4 mAb
Peripheral blood lymphocytes (PBLs) were isolated from
PBMCs upon 2 h plastic adherence at 37uC to remove the
majority of monocytes. PBLs (26105 cells/100 mL/tube) were pre-
incubated for 10 min at room temperature with nil or an anti-
CD4 mAb (clone Q4120, Progenics) and then incubated for 1 h at
room temperature with trimeric wt Env (250 nM) or wt Env which
had been pre-incubated for 10 min with the indicated amounts of
Tat. After 30 min, PBLs were extensively washed, stained with an
anti-gp120 mAb FITC (US Biological, H6003-34J3) for 30 min at
4uC, washed, fixed with paraformaldeyde and analyzed by flow
cytometry. Results were expressed as Env-binding positive cells.
Surface Plasmon Resonance (SPR) Assay
SPR assays were performed using a BIACORE 3000 (Biacore
AB, Uppsala, Sweden). Tat was immobilized using amine coupling
onto the CM3 sensor chip. As a positive control for the quality and
activity of the Env molecules, four domains soluble CD4 was
immobilized using amine-coupling reaction onto the same sensor
chip. The Env to Tat association was assessed by flowing different
concentrations of Env (5–1,000 nM) in PBS buffer, pH 7.4, with
0.2% Tween 20, 300 mM NaCl, and 5 mg/mL dextran. The
non-specific association of Env to Tat was determined using a
control surface without any ligand. Soluble CD4, an anti-CD4
mAb, and recombinant spike protein of the SARS virus were used
as negative controls. Sensor data were prepared for kinetics
analysis by subtracting binding responses collected from a blank
Figure 9. Tat/Env binding kinetics and thermodynamics. (A) Binding kinetics of trimeric wt Env (tw Env), trimeric DV2 Env (tDV2 Env),
monomeric wt Env (mwt Env) or monomeric DV2 Env (mDV2 Env) to Tat bound to the Biacore chip. The range of concentrations of Env molecules is
indicated. (B) Tat/Env binding thermodynamics by ITC. Tat was titrated with trimeric wt Env. The top panel shows calorimetric data versus time; the
lower panel shows integrated areas normalized to the number of moles of Env subunits injected at each injection step.
doi:10.1371/journal.pone.0048781.g009
Table 1. Rate and affinity constants for Tat/Env binding
determined by surface plasmon resonance.
kon
(M21s21) koff (s
21) T1/2 (min) Kd (M)
trimeric DV2 Env/Tat 2.66103 5.061025 230 2.261028
trimeric wt Env/Tat 1.46104 4.961024 23 3.861028
monomeric DV2 gp120 - Tat 5.96103 4.961024 23 9.161028
kon, association rate constant; koff, dissociation rate constant; T1/2, complex
dissociation half life; Kd, binding dissociation constant. No binding was
observed with monomeric wt Env.
doi:10.1371/journal.pone.0048781.t001
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reference surface. The association and dissociation phase data
were fitted simultaneously to a single-site model by using the
nonlinear data analysis program Biaevaluation 4.01 (Biacore AB,
Uppsala, Sweden).
Isothermal Titration Calorimetry
Isothermal titration calorimetry was performed on a VP-ITC
(Microcal LLC, Northampton, MA). Proteins were suspended in
PBS pH 7.4 and Tat (1.25 to 4.4 mM) was loaded into the cell with
trimeric Env (12.5-to 47.0-mM in protein subunit) in the syringe.
All runs were adjusted for heat of dilution and mixing. Binding
isotherms were auto-fitted to a baseline using the OriginH
software. For V3 loop, recombinant Tat and cyclic (heat-to-tail)
or linear V3 loop peptides lacking cysteins were suspended in PBS
(pH 7.4) containing 5 mM DTT. Twenty-eight mM Tat was
titrated at 20uC with a 260 mM peptide solution. The heat of
dilution of the peptide was subtracted and the binding isotherm
determined with the Origin software.
Modeling and Docking Calculations
Structural models of (i) the Tat protein (BH10) and (ii) the
gp120 DV1-2 domain of Env (SF162) in the CD4-free form, were
generated with the Modeller8 program [54] starting from the
available structure coordinates (see below) (Table S2), and
optimized through energy minimization with AMBER8 [55]. To
map the conformational variability of the Tat protein, three
different models were built on the basis of the three available
NMR structures [56,57] that, in spite of their high pair-wise
sequence identity (.77%), show different conformations (the
average RMSD among the three structures, calculated on the
average NMR structures, is 5.9 A˚). The core of the CD4-free form
of the gp120 Env protein was modeled on the DV1-2-3 SIV gp120
structure [58] and the V3 loop added using as template the V3
loop present in the CD4-bound DV1-2 HIV-1 gp120 structure
[59]. To sample the range of accessible conformations for the V3
loop, a 10 ns long molecular dynamics simulation was performed
on the gp120 Env DV1-2 structural model (details in Table S3),
and an ensemble of 50 different Env conformations was selected
and used for subsequent Tat/Env docking calculations. Models of
the Tat/Env complex were at first calculated with the BIGGER
[60] and ClusPro programs [61]. The interaction surfaces
resulting from these calculations, all of which consistently included
the V3 loop, were then used as input for Ambiguous-restraints
Driven Docking calculations of the Tat/Env complex, with the
HADDOCK program [62] (Table S4). This program was also
used for modeling the complex between integrin avb3, whose
structure is available in the pdb (pdb identifier: 1L5G) [63] and the
energy minimized structures of Tat. For this complex, both
unambiguous and ambiguous restraints were used (Table S5), the
former being derived from the structure of an adduct between
integrin and a cyclic peptide containing the RGD sequence [63].
The ternary complex Tat/Env (DV1-2) was derived by superim-
posing Tat in the binary complexes Tat/Env (DV1-2) and Tat in
the binary complex Tat/integrin avb3 and generating a structural
model which involves Tat, Env (DV1-2) and integrin avb3.
ELISA for Binding of V3 Peptides to the Tat Protein
Microtiter ELISA plates were coated with 100 ng per well of
Tat in a 100 mL volume of Dulbecco’s PBS containing Ca2+ and
Mg2+ for 1 h at 37uC. Plates were washed and blocked with
control buffer for 2 h at room temperature. Wells were then
incubated with different concentrations of a cyclic or a linear V3
Figure 10. Tat/Env complex and ternary Tat/Env/avb3 complex by modeling-docking calculations. (A) ribbon representation of the Tat/
Env complex showing that the Env CD4 binding site and the RGD domain of Tat are both exposed. Color code: DV1-2 Env: blue; Tat: red; Tat-RGD:
yellow. (B) Surface representation of the ternary Tat/Env/avb3 complex. Color code: DV1-2 Env: green; Tat: purple; avb3 integrin: grey. See
experimental procedures for details.
doi:10.1371/journal.pone.0048781.g010
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peptide lacking cysteins in blocking buffer for 1 h at 37uC. After
washing, plates were incubated with a primary Ab (rabbit anti-V3
serum 1:1,000) for 1 h at 37uC, incubated with anti-rabbit-
peroxidase Ab (SIGMA) (1:2,000) for 1 h at 37uC and developed
with ABTS substrate (Roche). Results were expressed in optical
density (OD).
Figure 11. Tat/V3 loop interaction by ELISA and ITC (A). Tat interaction with cyclic (open circles) or linear (filled circles) V3 peptides by ELISA.
Data are expressed as O.D. corrected for wells coated with the Tat buffer. (B) Tat interaction with cyclic (left panels) or linear (right panels) V3 peptides
by ITC. Upper panels: calorimetry data versus time; lower panels: integrated areas normalized to the number of moles of V3 loop injected at each
injection step.
doi:10.1371/journal.pone.0048781.g011
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Neutralization of Tat/Env Entry in MDDCs by Anti-Tat Ab
Negative or Ab Positive Sera from HIV-infected
Asymptomatic or Tat-vaccinated Subjects or from Tat/
Env-vaccinated Monkeys
For experiments with human anti-HIV sera, sera containing or
not anti-Tat Abs from asymptomatic HIV-infected individuals or
from vaccinees (at baseline or 48 weeks after the first immuniza-
tion) of ISS T-002 therapeutic trial were used.
The ISS T-002 (ClinicalTrials.gov NCT00751595) is a
randomized, open-label, phase II clinical trial with the
biologically active HIV-1 Tat protein conducted in 168 HIV-
1-infected HAART-treated anti-Tat Ab negative subjects, with
undetectable levels of plasma viremia (,50 copies/mL) since the
last 6 months prior to enrollment, CD4+ T cell number $200
cells/mL and known pre-HAART CD4 nadir [13]. The ISS T-
002 clinical trial was approved by the competent authority
(General Director of the Coordinator Clinical Center, Policli-
nico of Modena, Modena) and by the Ethics Committees of
each participating clinical center (Policlinico of Modena,
Modena; Arcispedale S. Anna, Ferrara; Istituti Fiosterapici
Ospitalieri San Gallicano, Rome; Policlinico of Bari, Bari;
Figure 12. Uptake of trimeric DV3 Env by MDDCs and block by anti-integrins mAbs. Uptake of DV2 Env or DV3 Env pre-incubated with
buffer or increasing concentrations of Tat, in the presence or absence of anti-integrin mAbs (10 mg/mL each) or a control isotype mAb (30 mg/mL).
Trimeric DV2 Env: circles; trimeric DV3 Env: squares. Control isotype Ab: open symbols; anti-integrin blocking mAbs combined: filled symbols.
doi:10.1371/journal.pone.0048781.g012
Figure 13. Neutralization of Tat/Env complex entry in MDDCs by sera from HIV-infected individuals. (A) Neutralization of trimeric DV2
Env entry in MDDCs by sera from HIV-infected subjects in the presence or absence of Tat in anti-Tat Ab negative (n = 8) and anti-Tat Ab positive
(n = 8) subjects. The bars represent the percentage of entry of Env alone incubated in buffer (in blue) or with Tat (in red). The percentage of Env-
positive cells is shown. Data are expressed as the mean with standard deviation of experiments performed in duplicate. The codes of the anti-Tat Ab
negative or positive sera are indicated at the bottom of the bars. (B) Geometric mean (GM) of the ratio, with 95% confidence interval (CI) of the
percentage of MDDCs internalizing Env in the absence (blue bar) or in the presence (red bar) of Tat in anti-Tat negative (n = 8) and anti-Tat positive
(n = 8) subjects. Statistical analysis was performed by the two-tailed Student’s t-test.
doi:10.1371/journal.pone.0048781.g013
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Ospedale S.M. Goretti Latina; Fondazione S. Raffaele, Milan;
Ospedale S. Maria Annunziata Florence; Ospedale Luigi Sacco,
Milan; Spedali Civili, Brescia; Ospedale A. di Savoia, Turin).
All subjects signed an informed consent at study entry.
Sera were diluted 1:30 in PBS and incubated for 60 min at
37uC with trimeric DV2 Env (0.4 mM) premixed for 10 min at
25uC with Tat (0.4 mM) or degassed PBS. The samples were then
added to MDDCs (26105 cells/mL) to a 1:5 final dilution. Cells
were then stained for intracellular Env and results expressed as the
percentage of Env positive cells. In these experiments Env was
added to the cells to a 0.08 mM final concentration, which
resulted in a higher percentage of positive cells for determining the
degree of inhibition of Env uptake by the sera. Due to the high cell
saturation level by Env, the degree of stimulation of Env uptake by
Tat was correspondingly lower. A pool of sera from six healthy
donors and a mAb against Tat (mAb 2A4.1, obtained from Dr Jon
Karn through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) were used as controls.
To assess the capability of mAb 2A4.1 to interfere with Tat uptake
by MDDCs, Tat was pre-incubated or not with molar excesses of
the mAb prior to the addition to MDDCs and then Tat uptake
determined by intracellular staining in flow cytometry.
For experiments with monkeys’ plasma, samples from Tat/Env
vaccinated or control monkeys at baseline (week 0) or after
immunization (week 38) were used. To assess the neutralization of
the Tat/Env complex entry in MDDCs, the same experimental
procedures described above for the human sera were used.
Statistical Methods
Viral RNA and proviral DNA in blood or tissues were
compared between vaccinated monkeys and controls by the one-
tailed Wilcoxon rank sum test. Percentage of MDDCs internal-
izing Env in the presence or absence of Tat in HIV infected anti-
Tat Ab negative or anti-Tat Ab positive subjects, as well as
changes from baseline of the percentage of MDDCs internalizing
Env in Tat-vaccinated trial subjects (ISS T-002) or in Tat/Env-
vaccinated monkeys were assessed by the two-tailed Student’s t-test
(log10 transformation was performed to normalize the data
distribution). Statistical analyses were carried out at the 0.05
significance level, using SASH software, version 9.2 (SAS Institute,
Cary, NC).
Results
Co-immunization of Cynomolgus Macaques with HIV-1
Tat and Env Proteins Blocks Systemic Spreading of an R5
Challenge Virus
To evaluate the effect of mucosal immunization with the Tat
and the oligomeric DV2 Env protein combination, cynomolgus
macaques were vaccinated twice intranasally with HIV-1 Tat and
Env, given together with the LT-K63 mucosal adjuvant, and then
boosted subcutaneously with Tat plus Env in Alum. Controls
received only the adjuvants by the same routes (Table S1).
Macaques were then challenged intrarectally with 70 MID50 of the
R5-tropic SHIVSF162P4cy using a virus stock adapted to cynomol-
Figure 14. Neutralization of Tat/Env complex entry or infection in MDDCs by sera from Tat-vaccinated HIV-infected individuals. (A)
Percentage of MDDCs internalizing Env in the presence of sera from trial subjects (n = 7) at baseline (week 0, anti-Tat Ab negative, in blue) and after
Tat vaccination (week 48, anti-Tat Ab positive, in red) in the absence (empty bars) or in the presence (filled bars) of Tat. The codes of the sera are
indicated at the bottom of the bars. (B) Geometric mean (GM) of the ratio (week 48 vs baseline), with 95% confidence interval (CI) of the percentage
of MDDCs internalizing Env in the presence or in the absence of Tat in trial subjects (n = 7). Statistical analysis was performed by the two-tailed
Student’s t-test. (C) MDDC infection performed in duplicate for 48 h with pSF162LUC in the presence of coated cys22 Tat (0.01 mM) or BSA (control)
with sera from a representative trial subject before (baseline, anti-Tat Ab negative) and after Tat vaccination (anti-Tat positive). Sera prior to or after
vaccination contained the same anti-Env Ab titers. Data are expressed as RLU.
doi:10.1371/journal.pone.0048781.g014
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gus macaques and titrated in vivo [41]. No infection or a
statistically significant reduction of viral loads and proviral DNA
were observed in the vaccinated monkeys as compared to controls
(Fig. 1 A–B and Table S6). Of note, proviral load in the inguinal
lymph nodes was significantly lower in vaccinated monkeys as
compared to controls, whereas it did not differ significantly in
rectal biopsies (Fig. 1C). Thus, mucosal vaccination with the Env
and Tat protein combination leads to an effective containment of
viral infection at the portal of entry, with block of virus
dissemination to lymph nodes following a very high rectal
challenge dose.
Figure 15. Neutralization of Tat/Env complex entry in MDDCs by sera from Tat/Env-vaccinated monkeys. (A) Percentage of MDDCs
internalizing Env in the presence of plasma from Tat/Env vaccinated or control monkeys (6 animals/group) before (week 0, anti-Tat Ab negative, in
blue) or after vaccination (week 38, anti-Tat Ab positive, in red) in the absence (empty bars) or in the presence (filled bars) of Tat. The codes of the
plasma are indicated at the bottom of the bars: MU1-6, vaccinated monkeys; MU7-12, control monkeys. (B) Geometric mean (GM) of the ratio (week
38 vs baseline), with 95% confidence interval (CI) of the percentage of MDDCs internalizing Env in the presence or in the absence of Tat in vaccinated
monkeys (n = 6). Statistical analysis was performed by the two-tailed Student’s t-test.
doi:10.1371/journal.pone.0048781.g015
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Extracellular Tat Enhances Infection of Monocyte-derived
Dendritic Cells (MDDCs) by Promoting Virus Entry
Since DCs are key cells at the portal of entry of HIV, and Tat is
known to act on them by binding to their RGD-integrin receptors,
we investigated whether Tat affects their susceptibility to virus
infection. To this goal, a single-cycle luciferase-expressing R5
HIV-1 (SF162LUC), pre-incubated or not with the transactiva-
tion-silent cys22 Tat protein (Fig. S1), was added to MDDCs from
different donors. The cys22 Tat was used to dissect effects of Tat
on virus infection other than its transactivation activity. The cys22
Tat enhanced HIV infection in MDDCs to a different extent
(ranging from 6.6 to 1.6 fold increase) according to the donor
(Fig. 2). Thus, Tat increases HIV infectivity in DCs by a novel,
transactivation-independent mechanism(s), suggesting that Tat can
increase virus entry.
To investigate the effect of extracellular Tat on HIV entry,
fluorescent VLPs, displaying on their surface native trimeric HIV-
1 Env from either the R5-tropic BaL or the X4-tropic HXBc2
strain (Env-VLPs), were pre-incubated with or without increasing
concentrations of the cys22 Tat protein and then added to
MDDCs. VLPs without Env (null-VLPs) were used as control. As
shown in Fig. 3A and B, the proportion of MDDCs positive for
Env-VLPs from both viruses markedly increased in the presence of
Tat. Confocal microscopy confirmed that Env-VLPs were
internalized by the cells (Fig. 3C). In contrast, the effect of Tat
on the entry of null-VLPs was negligible, ruling out an effect of Tat
on the endocytic pathway. In addition, Tat did not increase Env-
VLP internalization when was given at the same time of VLP
addition to MDDCs (data not shown), suggesting that Tat must be
already bound to Env-VLPs to observe internalization. This
indicated that Tat increases virus entry and suggested that the
increased VLP entry is receptor-mediated and dependent on Tat/
Env binding interactions.
Tat Released by Producing T cells Increases Entry and
Infection of a Replication-incompetent and Tat-
independent SF162-pseudotyped Virus
Tat is released by acutely infected cells and extracellular Tat is
present in tissues from infected subjects [14–21]. In order to
determine whether extracellular Tat produced by neighbor cells
could affect the entry of virus particles and infection independently
of its transactivating activity, a co-culture system was used in
which CEMss-Tat expressing cells (which do not express CCR5)
and TZM-bl cells, which are CCR5+, were co-cultured in the
presence or absence of a single-cycle, Tat-independent and GFP
expressing SF162 (VP/SF162) [64], as described in materials and
methods. As shown in Fig. 4, the MFI of GFP positive TZM-bl
cells was greatly enhanced only in the presence of CEMss-Tat
cells. Since CEMss cells do not express detectable levels of CCR5,
VP/SF162 could only infect the CCR5+ TZM-bl. Thus, Tat
Figure 16. Outcome of DC infection in the absence or presence of Tat, anti-Env and/or anti-Tat antibodies. Tat redirects HIV to RGD-
binding integrins evading neutralization by anti-Env Abs and both anti-Env and anti-Tat Abs are required to block infection. Extracellular Tat released
by infected neighbor cells binds to trimeric Env on HIV, decreasing recognition of C-type lectin receptors and promoting engagement of RGD-
binding integrins, which are expressed by inflammatory DCs, macrophages and endothelial cells (ECs) present at the site of infection. As a result,
virions escape neutralization by anti-Env Abs directed against high mannose determinants and enters target cells upon binding to RGD-binding
integrins. Anti-Tat Abs neutralize this binding, preventing virus entry through RGD-binding integrins. DC-SIGN: Dendritic Cell-Specific Intercellular
adhesion molecule-3-Grabbing Non-integrin; SIGN-R: homologue of DC-SIGN present on ECs; MR: mannose receptor.
doi:10.1371/journal.pone.0048781.g016
Tat Binds Env and Competes Anti-HIV-1 Antibodies
PLOS ONE | www.plosone.org 17 November 2012 | Volume 7 | Issue 11 | e48781
released by infected cells promotes the entry of virions into
neighbor cells, favoring spreading and dissemination of the
infection.
Extracellular Tat Coated on Beads Binds HIV Virus
Particles and Adherent Tat Increases Productive Infection
of MDDCs, which Efficiently Transmit the Virus to T cells
Once released, Tat binds the HSPG present on the ECM and
on the cell surface. Tat present in tissues is mostly bound whereas
its soluble form is estimated to be lower [14,15,21]. In addition,
adherent Tat increases infection efficiency of T cells by both X4
and R5 HIV strains in a transactivation-independent manner [33].
To investigate whether adherent Tat is capable to bind HIV
virions, latex beads were coated with the Tat protein or its buffer,
and virus (HXBc2) added. After extensive washes, beads were
analyzed by immuno-Scanning Electron Microscopy using an
anti-gp-120 mAb. The backscattered electron imaging revealed
that HIV particles were bound only to Tat-coated beads, whereas
no virus was found on beads pre-incubated with the Tat buffer
containing BSA (Fig. 5A). Thus, immobilized Tat binds and
retains very efficiently HIV virus particles.
To determine whether adherent Tat, which mimicks the
biologically relevant form found in tissues, is capable of mediating
on MDDCs the effect observed with the soluble protein, infection
experiments were carried out using non tissue-culture plates in
which wells had been coated with Tat or BSA (control). As shown
in Fig. 5B, MDDC infection with SF162 HIV onto Tat-coated
wells resulted in a several fold increase of productive cell infection,
as determined by measuring p24 content in the cell supernatants,
as compared to cells in wells coated with BSA. Thus, as the soluble
form, adherent Tat promotes HIV entry and productive infection
of MDDCs. Moreover, the viral progeny from these cells was
highly infectious, as determined by the transmission of a
productive infection to T cells with supernatants of MDCCs
infected onto Tat-coated wells as compared to BSA-coated wells
(Fig. 5C).
This suggested that extracellular Tat present on virus particles
[33] or released by infected cells greatly contributes to the
acquisition and spreading of HIV infection. This occurs in a
transactivation-independent manner and by promoting virus entry
and productive infection of DCs. On note, infection of DCs would
be further amplified by endogenous Tat produced during
infection.
Antibodies to RGD-binding Integrins Neutralize Tat-
mediated Entry and Infection of MDDCs
Extracellular Tat targets and binds through its RGD region the
integrins a5b1, avb3 and avb5 expressed by DCs and other cells
of the reticular-endothelial system [22–29], and co-stains with
these integrins in tissues of HIV-infected individuals [14–20].
To elucidate the contribution of RGD-binding integrins in the
enhancing effect of Tat on MDDC infection, experiments were
performed with either soluble cys22 Tat or coated wt Tat with
MDDCs pre-incubated with a mixture of mAbs directed against
the a5b1, avb3 and avb5 integrins. BSA was used as control. As
shown in Fig. 6, anti-integrins mAbs efficiently neutralized the
enhancement of infection mediated by both soluble (Fig. 6A) or
adherent (Fig. 6B) Tat, indicating that they are involved in the
Tat-mediated virus entry and productive infection of DCs.
Tat Enters MDDCs through RGD-binding Integrins and
Targets Oligomeric Env to these Receptors
Since Tat enters very efficiently into MDDCs [29], experiments
were performed to determine whether this occurs through RGD-
binding integrins, and whether this could mediate entry of Tat-
bound virus particles or trimeric Env molecules.
As shown in Fig. 7, Tat entered very efficiently MDDCs, and
entry of both wt Tat (Fig. 7A) and cys22 Tat (Fig. 7B) was
completely blocked by a combination of mAbs directed against
these RGD-binding integrins. As shown in Fig. 7C, the anti-
integrin mAbs inhibited also Tat-mediated entry of Env-VLPs into
MDDCs. This suggested that Tat enhances HIV entry into
MDDCs via the integrin endocytic pathway after forming a
complex with Env.
This was addressed by intracellular staining upon incubation of
MDDCs with Tat or Env proteins alone or combined. As shown in
Fig. S2, Tat entry into MDDCs was not affected by any of the Env
proteins (oligomeric or monomeric) used, while it was completely
inhibited by the anti-integrin mAbs, confirming that binding of the
RGD region of Tat to integrins is required for Tat entry and that
this is not affected by the presence of Env.
With regard to Env, in the absence of Tat, all Env molecules
efficiently entered MDDCs upon binding to C-type lectin
mannose-binding receptors, as indicated by the inhibition of Env
entry by a mAb blocking DC-SIGN (dendritic cell-specific ICAM-
3 grabbing non-integrin) (Fig. S3). Notably, in the absence of Tat,
the entry of Env molecules was not affected by the anti-integrin
mAbs, confirming that they are not involved in the entry of Env
(Fig. 8A, S2 and S3). However, when Env molecules were pre-
incubated with increasing concentrations of Tat, the entry of Env
augmented in a Tat dose-dependent manner reaching rapidly a
plateau in the nanomolar range (Fig. 8A and S3C). This entry of
Env was efficiently blocked by the anti-integrin mAbs (Fig. 8A and
S3C). In particular, the proportion of Tat-mediated, integrin-
dependent Env entry was most pronounced with the trimeric DV2
Env as compared to trimeric wt Env or the monomeric DV2 Env,
and lowest with the monomeric wt Env (Fig. 8A). Of note, the
effects of Tat on trimeric Env were also observed with wt Envs
from both clade A and C (Fig. 8B). Finally, blocking of both
integrin and DC-SIGN receptors did not completely block the
entry of Env (Fig. S3C), suggesting either incomplete blocking of
the above receptors or, more likely, the existence of additional
minor binding and entry pathways. These data suggest a specific
interaction of Tat with Env determinants, which appear to be
better exposed by the trimeric Env, especially upon deletion of the
V2 loop, and to be conserved among different HIV clades.
Tat Forms a Stable High-affinity Complex with Trimeric
Env by Binding gp120 Subunits
Surface plasmon resonance (SPR) was then used to gain more
insights into the Tat/Env interaction. As shown in Fig. 9 and
Table 1, the binding profile and the rate constants indicated the
formation of stable complexes for both the trimeric wt (half-life:
23 min) (Fig. 9A, upper left panel) and trimeric DV2 Env (half-life:
230 min) (Fig. 9A, upper right panel) as well as for monomeric
DV2 Env (half-life: 23 min) (Fig. 9A, bottom right panel), but not
for monomeric wt Env, which did not appear to bind Tat in these
assays (Fig. 9A, bottom left panel). Thus, deletion of the V2 loop
increases the affinity and/or stability of the complex in both
trimeric Env and monomeric gp120 (Table 1), explaining the
differences observed in the DC uptake experiments.
To determine the number of Tat binding sites on gp120,
isothermal titration calorimetry (ITC) was performed with trimeric
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wt Env. As shown in Fig. 9B, the binding isotherm indicated a 1:1
stoichiometry, with one molecule of Tat bound per gp120 subunit
in the trimer. In substantial agreement with SPR measurements, a
Kd of 111643 nM was determined.
Tat Binds Env Domains Overlapping Both the V3 Loop
and the CCR5-binding Sites
To localize the region of Env recognized by Tat, structural
models for the interaction of the two proteins were determined by
docking calculations. To model the two partner proteins,
templates derived from experimental structures were used. For
monomeric gp120 Env DV1-2 a structural model was derived
from the X-ray structures of both an unliganded (not CD4-bound)
simian immunodeficiency virus gp120 and a V3 loop from a
liganded HIV gp120 (see experimental procedures for details); for
the Tat structural model all the available solution structures were
used after energy minimization and molecular dynamics. For the
docking calculations it resulted that the interaction region of Env
with Tat consistently included the V3 loop (Fig. 10 and Fig. S4). In
particular, this interaction region included both sides of the V3
stem loop, which is one of the two main CCR5-binding regions of
Env, suggesting that Tat recognizes a bent V3 loop conformation
(Fig. 10A and Fig. S4). In these models the interaction occurred
with Tat residues spanning the Cys-rich region (aa 22–37).
Importantly, the C-terminal part of Tat containing the RGD
sequence remained free as needed for integrin binding (Fig. 10 and
Fig. S5 and S6), as shown by the structural model of a ternary
complex of Tat and Env with the avb3 integrin (Fig. 10B and Fig.
S5). Further, in these models the CD4-binding region of Env was
also free and not buried into the complex (Fig. 10), as confirmed
by blocking the CD4 binding of the Tat/Env complex to
peripheral blood lymphocytes (PBL) by a mAb against CD4
(Fig. S7).
The validity of these complex models was then verified by
ELISA and ITC experiments using a cyclic or a linear V3 loop
peptide. As shown in Fig. 11, the cyclic but not the linear
peptide bound Tat both in ELISA (Fig. 11A) and ITC
(Fig. 11B). In addition, the ITC binding isotherm indicated a
1:1 stoichiometry as for the interaction with trimeric Env. This
confirmed a direct interaction between Tat and the V3 loop in
a bent conformation.
The role of the V3 loop in the Tat/Env interaction was further
analyzed by using a trimeric Env carrying a deletion in the V3
loop (trimeric DV3 Env) and by comparing its uptake by MDDCs
with that of trimeric DV2 Env, in the presence or absence of the
anti-integrin mAbs. The internalization of DV3 Env was not
enhanced by Tat, nor was affected by the anti-integrin mAbs
(Fig. 12). Thus, the V3 loop is necessary for the formation of a
stable interaction of Env with Tat.
Modeling-docking calculations also identified additional inter-
actions in the inner domain of Env in proximity to the outer
domain and the other CCR5 binding region of Env (Fig. S8),
suggesting that Tat interacts and/or modifies both CCR5-
binding regions of Env. In fact, a lower Kd was found for Tat
interaction with the cyclic V3 loop peptide as compared to the
whole Env (Fig. 9A and 11B), and an increased stability of the
complex was detected upon V2 deletion, which is known to
unmask this co-receptor binding region of Env (Fig. 9A upper
right panel). Thus, Tat appears to bind and/or overlap to both
CCR5 binding regions of Env, and, upon these interactions, to
induce conformational changes in Env leading to exposure of
new epitopes.
Anti-Tat Abs are Essential to Neutralize the Tat-mediated
Env Entry and Virus Infection of MDDCs and to Restore
and Enhance Neutralization by HIV Sera
The previous results indicated that Tat directs virus particles to
the RGD-binding integrin endocytic pathway via a mechanism
that is independent of Env and DC-SIGN-mediated virus entry,
diverting the virus into a Tat-driven and integrin-mediated
pathway, which is highly efficient for infection of antigen-
presenting cells such as DCs.
By directing HIV to RGD binding integrins and/or by shielding
Env, Tat may divert Ab responses blocking the Env and the DC-
SIGN entry pathway, which is believed to play a key role in T cell
trans-infection. To test this hypothesis, sera from asymptomatic
HIV infected individuals, positive for Abs against Env and
negative or positive for Abs against Tat, were used in Tat/Env
DC entry experiments. Sera were mixed with oligomeric DV2 Env
in the presence or absence of Tat prior to the addition to MDDCs.
In the absence of Tat, sera showed a variable level of inhibition of
Env entry in MDDCs (Fig. 13A) indicating that Abs against Env
can partially inhibit the interaction of Env with DC-SIGN.
However, sera from all subjects negative for anti-Tat Abs became
almost totally ineffective at inhibiting Env entry into MDDCs in
the presence of Tat (Fig. 13A). In contrast, sera from all subjects
also positive for anti-Tat Abs remained neutralization effective in
the absence of Tat, and their effectiveness was greatly increased or
induced ex novo by Tat (Fig. 13A). Thus, in the presence of Tat,
anti-Env Ab positive but anti-Tat Ab negative sera lose their
neutralizing effect on virus entry, while the presence of both anti-
Env and anti-Tat Abs restores and significantly increases HIV
neutralization (Fig. 13B).
To determine whether Tat vaccination could induce anti-Tat
Abs capable of blocking Tat/Env entry and infection of MDDCs,
sera from HIV infected HAART-treated patients from a phase II
Tat therapeutic trial (ClinicalTrials.gov NCT00751595) [13] were
tested prior to and after vaccination. As shown in Fig. 14, Env
entry into MDDCs was partially blocked by the anti-Env Ab
positive and anti-Tat Ab negative sera collected at baseline from
the vaccinees. However, in the presence of Tat, neutralization of
Env entry by these sera was lost. In contrast, after Tat vaccination,
sera inhibited the effect of Tat on Env entry and further increased
neutralization (Fig. 14A), in a statistically significant manner
(Fig. 14B). Similar results were obtained in MDDC infection in the
presence of Tat (Fig. 14C), which reproduced the same pattern as
that observed for the Tat/Env entry assays, confirming that Tat
vaccination can induce anti-Tat Abs capable of blocking both
entry and infection mediated by Tat. In particular, sera abolished
the enhancement effect of Tat on DC infection which diminished
to the levels observed with BSA (negative control). In addition,
comparable results on cell infection were obtained with purified
anti-Tat rabbit polyclonal antibodies.
Finally, similar or identical results were also obtained with
plasma from Tat/Env vaccinated monkeys (Fig. 15), in that
plasma from vaccinated animals blocked the enhancement of Tat-
mediated entry of Env and further neutralized Env uptake, as
compared to their baseline or to control animals.
Thus, anti-Tat Abs are essential to neutralize the Tat and Env
complex entry and virus infection, and the presence of both anti-
Env and anti-Tat Abs, as occurring in Tat vaccinated HIV
infected patients or in Tat/Env vaccinated monkeys, is required to
block HIV entry and infection (Fig. 16).
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Discussion
In the present study, we found that mucosal vaccination with
the combination of Tat and Env proteins protected non-human
primates against an intrarectal challenge with a high dose of an
R5-SHIV. In particular, a highly significant containment of the
virus at the portal of entry was found in vaccinated monkeys as
compared to controls, with block of virus dissemination to lymph
nodes, the primary site for virus amplification and establishment of
the virus reservoir. Following this, we found that extracellular Tat,
both soluble and adherent, was able to increase both R5 and X4
HIV entry and infection of DCs, a major HIV cell target present
at the mucosal portal of entry. This action of Tat is transactiva-
tion-independent, and is due to the formation of a molecular
complex between Tat and trimeric Env. By increasing entry of
trimeric Env, Tat bound to virus particles increases virus infection
of DCs and, at the same time, redirects HIV from the canonical
receptors to the RGD-binding integrins a5b1, avb3 and avb5.
These integrins are highly expressed by DCs and macrophages
[65–71] and by activated endothelia [17,22–28], which mediate
the extravasation of activated lympho-monocyte at inflammation
sites [72]. In addition, these effects of Tat are observed in the pico-
nanomolar protein range, consistent with the levels detected in
sera and tissues of HIV infected subjects [14–21], strongly
suggesting that they are biologically relevant.
The present data indicate that Tat can increase the chances of
acquiring HIV infection by increasing virus infectivity of DCs and
other key cells at the portals of entry, and, at the same time, by
driving the virus to mucosal sites rich of these cells, which, in turn,
activate target T cells present at, or proximal to, the virus portals
of entry [73]. This would favor the creation of a local focus of self-
perpetrating infection, increasing productive infection and virus
dissemination to regional lymph nodes, while limiting the
dispersion of viral progeny in tissues poor of target cells. Of note,
most of the data shown are by using a csy22 Tat, which is
transactivation-silent. This was necessary to dissect the entry effect
of Tat from its transactivation activity. However, since wt Tat
protein is also the most potent transactivator of HIV gene
expression and replication, this activity will further amplify virus
infection and dissemination promoted by extracellular Tat [15].
The Tat/Env complex is stably formed only with trimeric Env
molecules which are present in a little number only on viral
particles, whereas monomeric gp120, which is shed in large
amounts by both HIV and infected cells, is not well recognized by
Tat and, therefore, does not compete with the virus for binding
extracellular Tat. In this regard, previous data suggested that cell
membrane bound Tat specifically binds the V2 loop of monomeric
gp120, promoting HIV-1 infection and spreading [74]. In our
system, the V2 loop is not required for complex formation, and its
deletion increases the stability of the complex by about ten-fold,
suggesting that V2 partially shields the Tat binding site and its
removal stabilizes the Tat/Env interactions. This is consistent with
the role of V2 in shielding the V3 Env region.
The Tat/Env complex formation is mediated by interactions of
Tat with the CCR5-binding regions of Env, including the V3 loop
and a region of Env partially overlapping the other Env CCR5-
binding site, as suggested by modeling-docking calculations and
indicated by the direct binding of Tat to a cyclic V3 loop peptide,
and by the lack of enhancement of HIV entry in MDDCs by
trimeric DV3 Env.
Of importance, Tat binds trimeric Env molecules from different
HIV clades (A, B, C).
Finally, the presence of Tat abolishes neutralization of Env
entry and infection of DCs by HIV sera lacking anti-Tat Abs.
However, when anti-Tat Abs are also present, neutralization is not
only restored but further increased. The same is observed with sera
from anti-Tat/Env vaccinated monkeys.
The present findings have major implications for both HIV
pathogenesis as well as vaccine design: i) the binding of Tat to
Env may be pivotal to the establishment of a persistent infection
in the host by increasing the local virus load using cells that are
key at the portal of entry and by sustaining virus replication and
dissemination into tissues [73]; of note, these are the cells that
become the virus reservoir in chronic infection; and ii) since Tat
binds Env in a region that includes both the CCR5-binding sites,
the complex may act by shielding key epitopes for neutralizing
Abs induced by the virus during natural infection or elicited by
Env-based vaccines. Further, the Tat/Env complex interaction
will also likely expose new Env epitopes that are unlikely to be
recognized by Abs elicited by Env alone in preventative vaccine
approaches. This may explain the lack or marginal protection
observed with Env-based vaccines in phase III efficacy studies
[1,2,3].
Thus, extracellular Tat has a key function to secure HIV
infection by redirecting the virus to cells capable of establishing
productive infection, HIV dissemination, and virus reservoirs
and, at the same time, by promoting virus escape from Env
neutralization. Paradoxically, in the absence of anti-Tat Ab
responses, as occurring in most HIV infected individuals, these
mechanisms may be further increased by anti-Env Abs alone
since block of virus entry via DC-SIGN may favor, in the
presence of Tat, the integrin-mediated virus entry pathway. By
binding surface glycoproteins HIV Tat might contribute to
enhance susceptibility to co-infecting pathogens in HIV infected
patients. On the other hand, the Tat/Env complex is highly
stabilized upon V2 loop deletion, which resembles the reported
V1/V2 shortening of early virus isolates in newly infected
subjects [75-78]. Since V1/V2 deletions are known to expose
both the V3 and the other CCR5 binding region of Env to both
the co-receptor and to specific neutralizing Abs [44,79–82],
these isolates may form the most stable complex with Tat
in vivo, be facilitated for transmission and, at the same time, be
shielded from the mounting humoral response. This may also
explain the correlation of the anti-Tat humoral response with
non progression to disease found in both cross-sectional and
longitudinal studies in HIV-infected individuals [38,83]. At the
same time, the present data shed light on the mechanisms of
protection of monkeys vaccinated with the native Tat protein
[4–9,39], the protection from high dose virus challenge of
monkeys vaccinated with replication-competent adenoviruses
expressing Tat and Env [40], as well as the promising efficacy
results seen in the phase II therapeutic trial with Tat in
HAART-treated subjects [13]. Of note, anti-Tat Abs from
vaccinated and HIV-infected individuals are effective in
blocking Tat/Env entry and infection of DCs, indicating that
proper anti-Tat Abs can be induced by vaccination. Since anti-
Env Abs are already present in HIV-1 infected individuals, these
data suggest that Tat alone should be administered for
therapeutic vaccine strategies, whereas both Tat and Env
should be given combined for preventative vaccination.
In view of these results, a new phase II trial has been initiated in
South Africa in HAART-treated patients (ISS T-003, Clinical-
Trials.gov NCT01513135), and complexes of Tat and DV2 Env
are being tested in a multicentric preventative phase I trial in Italy
(ISS P-002, ClinicalTrials.gov NCT01441193, http://www.
hiv1tat-vaccines.info).
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Supporting Information
Figure S1 Wt Tat, but not cys22 Tat, transactivates HIV-1 LTR
in TZM-bl cells. RLU in HIV-1 LTR expressing TZM-bl cells
cultured in the presence of buffer, or 0.1, 1, 10 mM wt Tat or cys22
Tat.
(TIF)
Figure S2 Entry of wt Tat in MDDCs in the presence of
different Env molecules and block by anti-integrins antibodies.
Clade B trimeric wt Env (twt Env), trimeric DV2 Env (tDV2 Env),
monomeric wt Env (mwt Env), or monomeric DV2 Env (mDV2
Env) molecules or buffer were incubated with Tat and added to
MDDCs pre-treated with anti-integrin mAbs or a control isotype
mAb. Cells were then stained for intracellular Tat and results
expressed as the percentage of Tat-positive cells.
(TIF)
Figure S3 Block of trimeric DV2 Env or Tat/DV2 Env entry in
MDDCs by anti-DC-SIGN and anti-integrins antibodies. (A)
MDDCs from two different donors were pre-incubated with
different concentration of an anti-DC-SIGN mAb (20 or 50 mg/
mL) or with a control isotype mAb and then 70 nM (donor 1) or
35 nM (donor 2) trimeric DV2 Env (SF162) were added for
10 min prior to Env intracellular staining and flow cytometry
analysis. (B) MDDCs were pre-incubated with an anti-DC-SIGN
mAb (50 mg/mL), with anti-integrin mAbs (10 mg/mL each) or a
control isotype mAb, and then trimeric DV2 Env (70 nM) (SF162)
was added for 10 min prior to Env intracellular staining and flow
cytometry analysis. (C) MDDCs were pre-incubated with anti-DC-
SIGN mAb (50 mg/mL), anti-integrin mAbs (10 mg/mL each),
both, or a control isotype mAb and then incubated for 10 min
with trimeric DV2 Env (70 nM) previously complexed with Tat at
different concentrations (50, 16.67 and 5.56 nM) prior to Env
intracellular staining and flow cytometry analysis. Results are
expressed as the percentage of Env-positive cells.
(TIF)
Figure S4 Structural model of the DV1-2 Env/Tat binary
complex. Color code: Env: dark blue; Env V3-loop: light blue;
Tat: yellow; Tat cysteine-rich region: orange; and Tat RGD
segment: red. (A) panels: surface representation; (B) panels:
cartoon representation. See experimental procedures for details.
(TIF)
Figure S5 Structural Model of the DV1-2 Env/Tat/Integrin
avb3 Ternary Complex. Color code: DV1-2 Env: violet; Tat:
yellow; integrin avb3: cyan.
(TIF)
Figure S6 Blockade of Tat/Env complex entry into MDDCs by
anti-Tat antibodies. Trimeric DV2 Env was incubated with PBS, a
pool of sera from six HIV uninfected healthy donors, the same
pool of sera plus the anti-Tat 2A4.1 mAb, Tat, or Tat plus 2A4.1
mAb, and added to cells. Cells were then stained for intracellular
Env and analyzed by flow cytometry. The percentage of Env-
positive cells is shown.
(TIF)
Figure S7 Blockade of Tat/Env complex binding in PBL by
anti-CD4 antibodies. PBLs were pre-incubated with buffer or an
anti-CD4 mAb and then incubated with twt Env or with twt Env
which had been pre-incubated with the indicated amounts of Tat.
PBLs were then stained with an anti-gp120 mAb and analyzed by
flow cytometry. The percentage of Env-binding cells is shown.
(TIF)
Figure S8 Env and Tat interacting residues according to
modeling docking analyses. Upper panel: Env interacting residues
in the five lowest energy solutions. Residues involved in
interactions are indicated by boxes. Different box colors
correspond to different solutions. Secondary structure elements
are colored as follows: the DV1-2 gp120 inner domain of Env
substructures are represented in yellow (a1 helix), red (bridging
sheet strands), white (three-strand sheet), purple (outer/inner
domain transition), and green (a5 helix), while the outer domain is
depicted in blue. Lower panel: Tat interacting residues in the five
lowest energy solutions. Residues involved in interactions are
indicated by boxes in five different colors. Tat regions are colored
as follows: purple (N-terminal region), green (cysteine-rich region),
yellow (protein core), red (basic region), and grey (C-terminal
region).
(TIF)
Table S1 Vaccine protocol design and schedule of immuniza-
tion of cynomolgus monkeys.
(DOCX)
Table S2 Structures used as templates to model the structures of
Tat and Env.
(DOC)
Table S3 Parameters used to perform MD simulations on the
V3 loop of the Env protein.
(DOC)
Table S4 Parameters used to perform docking calculations.
(DOC)
Table S5 Parameters used to perform docking calculations.
(DOC)
Table S6
CD4+ T cell counts, plasma viral load and proviral DNA load in
blood, inguinal lymph nodes and rectal mucosal tissues at 4 week
after intrarectal challenge with 70 MID50 of SHIVSF162P4cy.
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